At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

New AI tool from UC San Diego and collaborators precisely maps the urethra on MRI to make prostate cancer radiation safer and reduce urinary side effects. Running on SDSC’s Expanse supercomputer, the ...

A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously stopped being receptive to treatment finding their tumours shrinking, ...

Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...